ScripBiogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on Ju
ScripWho: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C
Pink SheetThe Biden Administration’s policies on price inflation rebates in Medicare and Medicaid unintentionally provided President Trump a tool to amplify the threat tariffs would pose to pharma. But Trump’s
ScripExelixis may have a steady source of revenue after cabozantinib – approved as Cabometyx and Cometriq – loses market exclusivity, after zanzalintinib delivered positive pivotal Phase III results in col